GENTAUR Belgium BVBA BE0473327336 Voortstraat 49, 1910 Kampenhout BELGIUM Tel 0032 16 58 90 45
GENTAUR U.S.A Genprice Inc,Logistics 547 Yurok Circle, SanJose, CA 95123
Tel (408) 780-0908, Fax (408) 780-0908, [email protected]

Did you know ? If you order before Friday 14h we deliver 90PCT of the the time next Tuesday, Gentaur another in time delivery

Vasopressin-neurophysin 2-copeptin (AVP-NPII) [Cleaved into: Arg-vasopressin (Arginine-vasopressin); Neurophysin 2 (Neurophysin-II); Copeptin]

 NEU2_HUMAN              Reviewed;         164 AA.
P01185; A0AV35; O14935;
21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
01-AUG-1992, sequence version 2.
13-FEB-2019, entry version 200.
RecName: Full=Vasopressin-neurophysin 2-copeptin;
AltName: Full=AVP-NPII;
Contains:
RecName: Full=Arg-vasopressin;
AltName: Full=Arginine-vasopressin;
Contains:
RecName: Full=Neurophysin 2;
AltName: Full=Neurophysin-II;
Contains:
RecName: Full=Copeptin;
Flags: Precursor;
Name=AVP; Synonyms=ARVP, VP;
Homo sapiens (Human).
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
Catarrhini; Hominidae; Homo.
NCBI_TaxID=9606;
[1]
NUCLEOTIDE SEQUENCE [GENOMIC DNA].
PubMed=2991279;
Sausville E., Carney D., Battey J.;
"The human vasopressin gene is linked to the oxytocin gene and is
selectively expressed in a cultured lung cancer cell line.";
J. Biol. Chem. 260:10236-10241(1985).
[2]
NUCLEOTIDE SEQUENCE [MRNA].
PubMed=3768139;
Rehbein M., Hillers M., Mohr E., Ivell R., Morley S., Schmale H.,
Richter D.;
"The neurohypophyseal hormones vasopressin and oxytocin. Precursor
structure, synthesis and regulation.";
Biol. Chem. Hoppe-Seyler 367:695-704(1986).
[3]
NUCLEOTIDE SEQUENCE [MRNA].
PubMed=4065330; DOI=10.1016/0014-5793(85)80069-7;
Mohr E., Hillers M., Ivell R., Haulica I.D., Richter D.;
"Expression of the vasopressin and oxytocin genes in human
hypothalami.";
FEBS Lett. 193:12-16(1985).
[4]
NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT NDI VAL-48.
PubMed=1740104;
Bahnsen U., Oosting P., Swaab D.F., Nahke P., Richter D., Schmale H.;
"A missense mutation in the vasopressin-neurophysin precursor gene
cosegregates with human autosomal dominant neurohypophyseal diabetes
insipidus.";
EMBO J. 11:19-23(1992).
[5]
NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT VAL-119.
TISSUE=Lung carcinoma;
Du J., North W.G.;
"A missense mutation in the vasopressin mRNA with human small-cell
lung carcinoma.";
Submitted (OCT-1997) to the EMBL/GenBank/DDBJ databases.
[6]
NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
PubMed=11780052; DOI=10.1038/414865a;
Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R.,
Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,
Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M.,
Beasley O.P., Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J.,
Buck D., Burrill W.D., Butler A.P., Carder C., Carter N.P.,
Chapman J.C., Clamp M., Clark G., Clark L.N., Clark S.Y., Clee C.M.,
Clegg S., Cobley V.E., Collier R.E., Connor R.E., Corby N.R.,
Coulson A., Coville G.J., Deadman R., Dhami P.D., Dunn M.,
Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,
Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,
Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,
Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A.,
Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H.,
Rice C.M., Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S.,
Skuce C.D., Smith M.L., Soderlund C., Steward C.A., Sulston J.E.,
Swann R.M., Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A.,
Tracey A., Tromans A.C., Vaudin M., Wall M., Wallis J.M.,
Whitehead S.L., Whittaker P., Willey D.L., Williams L., Williams S.A.,
Wilming L., Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S.,
Rogers J.;
"The DNA sequence and comparative analysis of human chromosome 20.";
Nature 414:865-871(2001).
[7]
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
PubMed=15489334; DOI=10.1101/gr.2596504;
The MGC Project Team;
"The status, quality, and expansion of the NIH full-length cDNA
project: the Mammalian Gene Collection (MGC).";
Genome Res. 14:2121-2127(2004).
[8]
PROTEIN SEQUENCE OF 20-28, AND AMIDATION AT GLY-28.
PubMed=13591312;
Light A., du Vigneaud V.;
"On the nature of oxytocin and vasopressin from human pituitary.";
Proc. Soc. Exp. Biol. Med. 98:692-696(1958).
[9]
PROTEIN SEQUENCE OF 32-124.
PubMed=6574452; DOI=10.1073/pnas.80.10.2839;
Chauvet M.-T., Hurpet D., Chauvet J., Acher R.;
"Identification of human neurophysins: complete amino acid sequences
of MSEL- and VLDV-neurophysins.";
Proc. Natl. Acad. Sci. U.S.A. 80:2839-2843(1983).
[10]
PROTEIN SEQUENCE OF 126-164.
PubMed=7271787; DOI=10.1016/S0006-291X(81)80258-6;
Seidah N.G., Benjannet S., Chretien M.;
"The complete sequence of a novel human pituitary glycopeptide
homologous to pig posterior pituitary glycopeptide.";
Biochem. Biophys. Res. Commun. 100:901-907(1981).
[11]
VARIANT NDI THR-19.
PubMed=8370682; DOI=10.1210/jcem.77.3.8370682;
McLeod J.F., Kovacs L., Gaskill M.B., Rittig S., Bradley G.S.,
Robertson G.L.;
"Familial neurohypophyseal diabetes insipidus associated with a signal
peptide mutation.";
J. Clin. Endocrinol. Metab. 77:599A-599G(1993).
[12]
VARIANT NDI GLU-78 DEL.
PubMed=8103767; DOI=10.1210/jcem.77.3.8103767;
Yuasa H., Ito M., Nagasaki H., Oiso Y., Miyamoto S., Sasaki N.,
Saito H.;
"Glu-47, which forms a salt bridge between neurophysin-II and arginine
vasopressin, is deleted in patients with familial central diabetes
insipidus.";
J. Clin. Endocrinol. Metab. 77:600-604(1993).
[13]
VARIANT NDI THR-19.
PubMed=8514868; DOI=10.1172/JCI116494;
Ito M., Oiso Y., Murase T., Kondo K., Saito H., Chinzei T., Racchi M.,
Lively M.O.;
"Possible involvement of inefficient cleavage of preprovasopressin by
signal peptidase as a cause for familial central diabetes insipidus.";
J. Clin. Invest. 91:2565-2571(1993).
[14]
VARIANT NDI LEU-55.
PubMed=8045958; DOI=10.1210/jcem.79.2.8045958;
Repaske D.R., Browning J.E.;
"A de novo mutation in the coding sequence for neurophysin-II
(Pro24-->Leu) is associated with onset and transmission of autosomal
dominant neurohypophyseal diabetes insipidus.";
J. Clin. Endocrinol. Metab. 79:421-427(1994).
[15]
VARIANT NDI TRP-93.
PubMed=7714110; DOI=10.1210/jcem.80.4.7714110;
Nagasaki H., Ito M., Yuasa H., Saito H., Fukase M., Hamada K.,
Ishikawa E., Katakami H., Oiso Y.;
"Two novel mutations in the coding region for neurophysin-II
associated with familial central diabetes insipidus.";
J. Clin. Endocrinol. Metab. 80:1352-1356(1995).
[16]
VARIANTS NDI PHE-17; THR-19; VAL-19; ARG-45; CYS-51; GLY-78; PRO-81;
ARG-88; SER-88; SER-92 AND CYS-96.
PubMed=8554046;
Rittig S., Robertson G.L., Siggaard C., Kovacs L., Gregersen N.,
Nyborg J., Pedersen E.B.;
"Identification of 13 new mutations in the vasopressin-neurophysin II
gene in 17 kindreds with familial autosomal dominant neurohypophyseal
diabetes insipidus.";
Am. J. Hum. Genet. 58:107-117(1996).
[17]
VARIANT NDI VAL-54.
PubMed=9360520; DOI=10.1210/jcem.82.11.4231;
Gagliardi P.C., Bernasconi S., Repaske D.R.;
"Autosomal dominant neurohypophyseal diabetes insipidus associated
with a missense mutation encoding Gly23-->Val in neurophysin II.";
J. Clin. Endocrinol. Metab. 82:3643-3646(1997).
[18]
VARIANT NDI THR-19.
PubMed=9580132; DOI=10.1210/jcem.83.3.4658;
Calvo B., Bilbao J.R., Urrutia I., Eizaguirre J., Gaztambide S.,
Castano L.;
"Identification of a novel nonsense mutation and a missense
substitution in the vasopressin-neurophysin II gene in two Spanish
kindreds with familial neurohypophyseal diabetes insipidus.";
J. Clin. Endocrinol. Metab. 83:995-997(1998).
[19]
VARIANTS NDI PHE-87 AND TYR-92.
PubMed=9814475; DOI=10.1210/jcem.83.11.5278;
Grant F.D., Ahmadi A., Hosley C.M., Majzoub J.A.;
"Two novel mutations of the vasopressin gene associated with familial
diabetes insipidus and identification of an asymptomatic carrier
infant.";
J. Clin. Endocrinol. Metab. 83:3958-3964(1998).
[20]
VARIANT NDI LEU-26.
PubMed=10369876; DOI=10.1093/hmg/8.7.1303;
Willcutts M.D., Felner E., White P.C.;
"Autosomal recessive familial neurohypophyseal diabetes insipidus with
continued secretion of mutant weakly active vasopressin.";
Hum. Mol. Genet. 8:1303-1307(1999).
[21]
VARIANT NDI ARG-54.
PubMed=10487710; DOI=10.1210/jcem.84.9.5979;
Calvo B., Bilbao J.R., Rodriguez A., Rodriguez-Arnao M.D., Castano L.;
"Molecular analysis in familial neurohypophyseal diabetes insipidus:
early diagnosis of an asymptomatic carrier.";
J. Clin. Endocrinol. Metab. 84:3351-3354(1999).
[22]
VARIANTS NDI ARG-116 AND GLY-116.
PubMed=11017955;
Abbes A.P., Bruggeman B., van den Akker E.L.T., de Groot M.R.,
Franken A.A.M., Drexhage V.R., Engel H.;
"Identification of two distinct mutations at the same nucleotide
position, concomitantly with a novel polymorphism in the vasopressin-
neurophysin II gene (AVP-NP II) in two Dutch families with familial
neurohypophyseal diabetes insipidus.";
Clin. Chem. 46:1699-1702(2000).
[23]
VARIANT NDI TYR-59.
PubMed=11150885; DOI=10.1159/000023573;
Skordis N., Patsalis P.C., Hettinger J.A., Kontou M., Herakleous E.,
Krishnamani M.R., Phillips J.A. III;
"A novel arginine vasopressin-neurophysin II mutation causes autosomal
dominant neurohypophyseal diabetes insipidus and morphologic pituitary
changes.";
Horm. Res. 53:239-245(2000).
[24]
VARIANT NDI TYR-105.
PubMed=10677561;
Fujii H., Iida S., Moriwaki K.;
"Familial neurohypophyseal diabetes insipidus associated with a novel
mutation in the vasopressin-neurophysin II gene.";
Int. J. Mol. Med. 5:229-234(2000).
[25]
VARIANT NDI PRO-97.
PubMed=11748489; DOI=10.1055/s-2001-18994;
Mundschenk J., Rittig S., Siggaard C., Hensen J., Lehnert H.;
"A new mutation of the arginine vasopressin-neurophysin II gene in a
family with autosomal dominant neurohypophyseal diabetes insipidus.";
Exp. Clin. Endocrinol. Diabetes 109:406-409(2001).
[26]
VARIANT NDI GLY-116, AND CHARACTERIZATION OF VARIANT NDI GLY-116.
PubMed=11443218; DOI=10.1210/jcem.86.7.7686;
Nijenhuis M., van den Akker E.L.T., Zalm R., Franken A.A.M.,
Abbes A.P., Engel H., de Wied D., Burbach J.P.H.;
"Familial neurohypophysial diabetes insipidus in a large Dutch
kindred: effect of the onset of diabetes on growth in children and
cell biological defects of the mutant vasopressin prohormone.";
J. Clin. Endocrinol. Metab. 86:3410-3420(2001).
[27]
VARIANT NDI GLY-98.
PubMed=11161827; DOI=10.1006/mgme.2000.3117;
DiMeglio L.A., Gagliardi P.C., Browning J.E., Quigley C.A.,
Repaske D.R.;
"A missense mutation encoding cys(67) --> gly in neurophysin ii is
associated with early onset autosomal dominant neurohypophyseal
diabetes insipidus.";
Mol. Genet. Metab. 72:39-44(2001).
[28]
VARIANTS NDI ARG-54; TYR-92 AND ARG-105.
PubMed=11980620; DOI=10.1530/eje.0.1460649;
Rutishauser J., Kopp P., Gaskill M.B., Kotlar T.J., Robertson G.L.;
"Clinical and molecular analysis of three families with autosomal
dominant neurohypophyseal diabetes insipidus associated with a novel
and recurrent mutations in the vasopressin-neurophysin II gene.";
Eur. J. Endocrinol. 146:649-656(2002).
[29]
VARIANT NDI SER-92.
PubMed=12012274; DOI=10.1055/s-2002-29091;
Bullmann C., Kotzka J., Grimm T., Heppner C., Jockenhovel F.,
Krone W., Muller-Wieland D.;
"Identification of a novel mutation in the arginine vasopressin-
neurophysin II gene in familial central diabetes insipidus.";
Exp. Clin. Endocrinol. Diabetes 110:134-137(2002).
[30]
VARIANT NDI HIS-21.
PubMed=12107248; DOI=10.1210/jcem.87.7.8677;
Rittig S., Siggaard C., Ozata M., Yetkin I., Gregersen N.,
Pedersen E.B., Robertson G.L.;
"Autosomal dominant neurohypophyseal diabetes insipidus due to
substitution of histidine for tyrosine-2 in the vasopressin moiety of
the hormone precursor.";
J. Clin. Endocrinol. Metab. 87:3351-3355(2002).
[31]
VARIANT NDI PHE-104.
PubMed=12359138; DOI=10.1016/S1096-7192(02)00118-X;
Santiprabhob J., Browning J.E., Repaske D.R.;
"A missense mutation encoding Cys73Phe in neurophysin II is associated
with autosomal dominant neurohypophyseal diabetes insipidus.";
Mol. Genet. Metab. 77:112-118(2002).
[32]
VARIANT NDI THR-19.
PubMed=12519420; DOI=10.1046/j.1365-2265.2003.01667.x;
Boson W.L., Sarubi J.C., D'Alva C.B., Friedman E., Faria D.,
De Marco L., Wajchenberg B.;
"A signal peptide mutation of the arginine vasopressin gene in
monozygotic twins.";
Clin. Endocrinol. (Oxf.) 58:108-110(2003).
[33]
VARIANT NDI PRO-99.
PubMed=14510916; DOI=10.1046/j.1365-2265.2003.01834.x;
Elias P.C.L., Elias L.L.K., Torres N., Moreira A.C.,
Antunes-Rodrigues J., Castro M.;
"Progressive decline of vasopressin secretion in familial autosomal
dominant neurohypophyseal diabetes insipidus presenting a novel
mutation in the vasopressin-neurophysin II gene.";
Clin. Endocrinol. (Oxf.) 59:511-518(2003).
[34]
VARIANT NDI PHE-58.
PubMed=12931042; DOI=10.1159/000072526;
Wolf M.T.F., Doetsch J., Metzler M., Holder M., Repp R., Rascher W.;
"A new missense mutation of the vasopressin-neurophysin II gene in a
family with neurohypophyseal diabetes insipidus.";
Horm. Res. 60:143-147(2003).
[35]
VARIANT NDI SER-98.
PubMed=15538939; DOI=10.1530/eje.0.1510605;
Baglioni S., Corona G., Maggi M., Serio M., Peri A.;
"Identification of a novel mutation in the arginine vasopressin-
neurophysin II gene affecting the sixth intrachain disulfide bridge of
the neurophysin II moiety.";
Eur. J. Endocrinol. 151:605-611(2004).
[36]
VARIANTS NDI THR-19; VAL-19; ARG-54; ALA-67; GLY-78; GLU-78 DEL;
ASP-96; CYS-96; GLY-104 AND TRP-116.
PubMed=14673472; DOI=10.1038/sj.ejhg.5201086;
Christensen J.H., Siggaard C., Corydon T.J., deSanctis L., Kovacs L.,
Robertson G.L., Gregersen N., Rittig S.;
"Six novel mutations in the arginine vasopressin gene in 15 kindreds
with autosomal dominant familial neurohypophyseal diabetes insipidus
give further insight into the pathogenesis.";
Eur. J. Hum. Genet. 12:44-51(2004).
[37]
FUNCTION OF VASOPRESSIN, MUTAGENESIS OF GLY-28, AND SUBUNIT.
PubMed=18174156; DOI=10.1074/jbc.M706477200;
Dutertre S., Croker D., Daly N.L., Andersson A., Muttenthaler M.,
Lumsden N.G., Craik D.J., Alewood P.F., Guillon G., Lewis R.J.;
"Conopressin-T from Conus tulipa reveals an antagonist switch in
vasopressin-like peptides.";
J. Biol. Chem. 283:7100-7108(2008).
-!- FUNCTION: Neurophysin 2 specifically binds vasopressin.
-!- FUNCTION: Vasopressin has a direct antidiuretic action on the
kidney, it also causes vasoconstriction of the peripheral vessels.
Acts by binding to vasopressin receptors (V1bR/AVPR1B,
V1aR/AVPR1A, and V2R/AVPR2) (PubMed:18174156).
{ECO:0000269|PubMed:18174156}.
-!- SUBUNIT: Interacts with vasopressin receptors V1bR/AVPR1B (Ki=85
pM), V1aR/AVPR1A (Ki=0.6 nM) and V2R/AVPR2 (Ki=4.9 nM)
(PubMed:18174156). Interacts with oxytocin receptor (OXTR) (Ki=110
nM) (PubMed:18174156). {ECO:0000269|PubMed:18174156}.
-!- SUBCELLULAR LOCATION: Secreted.
-!- DISEASE: Diabetes insipidus, neurohypophyseal (NDI) [MIM:125700]:
A disease characterized by persistent thirst, polydipsia and
polyuria. Affected individuals are apparently normal at birth, but
characteristically develop symptoms of vasopressin deficiency
during childhood. {ECO:0000269|PubMed:10369876,
ECO:0000269|PubMed:10487710, ECO:0000269|PubMed:10677561,
ECO:0000269|PubMed:11017955, ECO:0000269|PubMed:11150885,
ECO:0000269|PubMed:11161827, ECO:0000269|PubMed:11443218,
ECO:0000269|PubMed:11748489, ECO:0000269|PubMed:11980620,
ECO:0000269|PubMed:12012274, ECO:0000269|PubMed:12107248,
ECO:0000269|PubMed:12359138, ECO:0000269|PubMed:12519420,
ECO:0000269|PubMed:12931042, ECO:0000269|PubMed:14510916,
ECO:0000269|PubMed:14673472, ECO:0000269|PubMed:15538939,
ECO:0000269|PubMed:1740104, ECO:0000269|PubMed:7714110,
ECO:0000269|PubMed:8045958, ECO:0000269|PubMed:8103767,
ECO:0000269|PubMed:8370682, ECO:0000269|PubMed:8514868,
ECO:0000269|PubMed:8554046, ECO:0000269|PubMed:9360520,
ECO:0000269|PubMed:9580132, ECO:0000269|PubMed:9814475}. Note=The
disease is caused by mutations affecting the gene represented in
this entry.
-!- SIMILARITY: Belongs to the vasopressin/oxytocin family.
{ECO:0000305}.
-!- WEB RESOURCE: Name=Wikipedia; Note=Vasopressin entry;
URL="https://en.wikipedia.org/wiki/Vasopressin";
-----------------------------------------------------------------------
Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
Distributed under the Creative Commons Attribution (CC BY 4.0) License
-----------------------------------------------------------------------
EMBL; M11166; AAA98772.1; -; Genomic_DNA.
EMBL; M25647; AAA61291.1; -; mRNA.
EMBL; X03172; CAA26935.1; -; mRNA.
EMBL; X62890; CAA44681.1; -; Genomic_DNA.
EMBL; AF031476; AAB86629.1; -; mRNA.
EMBL; AL160414; -; NOT_ANNOTATED_CDS; Genomic_DNA.
EMBL; X62891; CAA44682.1; -; Genomic_DNA.
EMBL; BC126196; AAI26197.1; -; mRNA.
EMBL; BC126224; AAI26225.1; -; mRNA.
CCDS; CCDS13045.1; -.
PIR; A39269; A39269.
PIR; B94676; NVHU2.
RefSeq; NP_000481.2; NM_000490.4.
RefSeq; XP_011527569.1; XM_011529267.1.
UniGene; Hs.89648; -.
ProteinModelPortal; P01185; -.
SMR; P01185; -.
BioGrid; 107032; 25.
IntAct; P01185; 2.
STRING; 9606.ENSP00000369647; -.
iPTMnet; P01185; -.
PhosphoSitePlus; P01185; -.
BioMuta; AVP; -.
DMDM; 128083; -.
PaxDb; P01185; -.
PeptideAtlas; P01185; -.
PRIDE; P01185; -.
ProteomicsDB; 51342; -.
Ensembl; ENST00000380293; ENSP00000369647; ENSG00000101200.
GeneID; 551; -.
KEGG; hsa:551; -.
CTD; 551; -.
DisGeNET; 551; -.
EuPathDB; HostDB:ENSG00000101200.5; -.
GeneCards; AVP; -.
HGNC; HGNC:894; AVP.
HPA; CAB025318; -.
HPA; HPA071892; -.
MalaCards; AVP; -.
MIM; 125700; phenotype.
MIM; 192340; gene.
neXtProt; NX_P01185; -.
OpenTargets; ENSG00000101200; -.
Orphanet; 30925; Hereditary central diabetes insipidus.
PharmGKB; PA25186; -.
eggNOG; ENOG410IXM5; Eukaryota.
eggNOG; ENOG4111S8B; LUCA.
GeneTree; ENSGT00390000004511; -.
HOGENOM; HOG000113768; -.
HOVERGEN; HBG004462; -.
InParanoid; P01185; -.
KO; K05242; -.
OMA; GLCCNSE; -.
OrthoDB; 1548839at2759; -.
PhylomeDB; P01185; -.
TreeFam; TF333018; -.
Reactome; R-HSA-1368108; BMAL1:CLOCK,NPAS2 activates circadian gene expression.
Reactome; R-HSA-388479; Vasopressin-like receptors.
Reactome; R-HSA-416476; G alpha (q) signalling events.
Reactome; R-HSA-418555; G alpha (s) signalling events.
Reactome; R-HSA-432040; Vasopressin regulates renal water homeostasis via Aquaporins.
Reactome; R-HSA-5619099; Defective AVP does not bind AVPR1A,B and causes neurohypophyseal diabetes insipidus (NDI).
Reactome; R-HSA-879518; Transport of organic anions.
Reactome; R-HSA-8856825; Cargo recognition for clathrin-mediated endocytosis.
Reactome; R-HSA-8856828; Clathrin-mediated endocytosis.
Reactome; R-HSA-9036092; Defective AVP does not bind AVPR2 and causes neurohypophyseal diabetes insipidus (NDI).
SIGNOR; P01185; -.
GeneWiki; Vasopressin; -.
GenomeRNAi; 551; -.
PMAP-CutDB; P01185; -.
PRO; PR:P01185; -.
Proteomes; UP000005640; Chromosome 20.
Bgee; ENSG00000101200; Expressed in 67 organ(s), highest expression level in hypothalamus.
Genevisible; P01185; HS.
GO; GO:0030665; C:clathrin-coated vesicle membrane; TAS:Reactome.
GO; GO:0005829; C:cytosol; TAS:Reactome.
GO; GO:0030425; C:dendrite; IEA:Ensembl.
GO; GO:0005576; C:extracellular region; TAS:Reactome.
GO; GO:0005615; C:extracellular space; IEA:Ensembl.
GO; GO:0030141; C:secretory granule; IEA:Ensembl.
GO; GO:0043027; F:cysteine-type endopeptidase inhibitor activity involved in apoptotic process; IDA:UniProtKB.
GO; GO:0005185; F:neurohypophyseal hormone activity; IEA:InterPro.
GO; GO:0005184; F:neuropeptide hormone activity; IDA:UniProtKB.
GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB.
GO; GO:0005102; F:signaling receptor binding; TAS:ProtInc.
GO; GO:0031894; F:V1A vasopressin receptor binding; IPI:UniProtKB.
GO; GO:0031895; F:V1B vasopressin receptor binding; IEA:Ensembl.
GO; GO:0007267; P:cell-cell signaling; TAS:ProtInc.
GO; GO:0070371; P:ERK1 and ERK2 cascade; IDA:UniProtKB.
GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
GO; GO:0006091; P:generation of precursor metabolites and energy; TAS:ProtInc.
GO; GO:0007625; P:grooming behavior; IEA:Ensembl.
GO; GO:0042538; P:hyperosmotic salinity response; IEA:Ensembl.
GO; GO:0007626; P:locomotory behavior; IEA:Ensembl.
GO; GO:0002125; P:maternal aggressive behavior; IEA:Ensembl.
GO; GO:0042711; P:maternal behavior; IEA:Ensembl.
GO; GO:0061024; P:membrane organization; TAS:Reactome.
GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB.
GO; GO:0043154; P:negative regulation of cysteine-type endopeptidase activity involved in apoptotic process; IDA:UniProtKB.
GO; GO:0007621; P:negative regulation of female receptivity; IEA:Ensembl.
GO; GO:0090201; P:negative regulation of release of cytochrome c from mitochondria; IDA:UniProtKB.
GO; GO:0051970; P:negative regulation of transmission of nerve impulse; IEA:Ensembl.
GO; GO:0043084; P:penile erection; IEA:Ensembl.
GO; GO:0030307; P:positive regulation of cell growth; IEA:Ensembl.
GO; GO:0008284; P:positive regulation of cell population proliferation; IEA:Ensembl.
GO; GO:0032849; P:positive regulation of cellular pH reduction; IEA:Ensembl.
GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; IEA:Ensembl.
GO; GO:0010628; P:positive regulation of gene expression; IDA:UniProtKB.
GO; GO:0014049; P:positive regulation of glutamate secretion; IEA:Ensembl.
GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IDA:UniProtKB.
GO; GO:0031394; P:positive regulation of prostaglandin biosynthetic process; IEA:Ensembl.
GO; GO:0003084; P:positive regulation of systemic arterial blood pressure; IEA:Ensembl.
GO; GO:0045907; P:positive regulation of vasoconstriction; IEA:Ensembl.
GO; GO:0070528; P:protein kinase C signaling; IDA:UniProtKB.
GO; GO:0035813; P:regulation of renal sodium excretion; IEA:Ensembl.
GO; GO:0003091; P:renal water homeostasis; TAS:Reactome.
GO; GO:0045471; P:response to ethanol; IEA:Ensembl.
GO; GO:0035094; P:response to nicotine; IEA:Ensembl.
GO; GO:0033574; P:response to testosterone; IEA:Ensembl.
GO; GO:0007165; P:signal transduction; IDA:UniProtKB.
GO; GO:0035176; P:social behavior; IEA:Ensembl.
GO; GO:0042310; P:vasoconstriction; IEA:UniProtKB-KW.
GO; GO:0006833; P:water transport; TAS:ProtInc.
Gene3D; 2.60.9.10; -; 1.
InterPro; IPR000981; Neurhyp_horm.
InterPro; IPR036387; Neurhyp_horm_dom_sf.
InterPro; IPR022423; Neurohypophysial_hormone_CS.
PANTHER; PTHR11681; PTHR11681; 1.
Pfam; PF00220; Hormone_4; 1.
Pfam; PF00184; Hormone_5; 1.
PIRSF; PIRSF001815; Nonapeptide_hormone_precursor; 1.
PRINTS; PR00831; NEUROPHYSIN.
ProDom; PD001676; Neurhyp_horm; 1.
SMART; SM00003; NH; 1.
SUPFAM; SSF49606; SSF49606; 1.
PROSITE; PS00264; NEUROHYPOPHYS_HORM; 1.
1: Evidence at protein level;
Amidation; Cleavage on pair of basic residues; Complete proteome;
Diabetes insipidus; Direct protein sequencing; Disease mutation;
Disulfide bond; Glycoprotein; Hormone; Polymorphism;
Reference proteome; Secreted; Signal; Vasoactive; Vasoconstrictor.
SIGNAL 1 19 {ECO:0000269|PubMed:13591312}.
PEPTIDE 20 28 Arg-vasopressin.
{ECO:0000269|PubMed:13591312}.
/FTId=PRO_0000020515.
CHAIN 32 124 Neurophysin 2.
{ECO:0000269|PubMed:6574452}.
/FTId=PRO_0000020516.
PEPTIDE 126 164 Copeptin. {ECO:0000269|PubMed:7271787}.
/FTId=PRO_0000020517.
SITE 28 28 Important for agonist activity on
V1aR/AVPR1A.
{ECO:0000269|PubMed:18174156}.
MOD_RES 28 28 Glycine amide.
{ECO:0000269|PubMed:13591312}.
CARBOHYD 131 131 N-linked (GlcNAc...) asparagine.
DISULFID 20 25
DISULFID 41 85 {ECO:0000250|UniProtKB:P01175}.
DISULFID 44 58 {ECO:0000250|UniProtKB:P01175}.
DISULFID 52 75 {ECO:0000250|UniProtKB:P01175}.
DISULFID 59 65 {ECO:0000250|UniProtKB:P01175}.
DISULFID 92 104 {ECO:0000250|UniProtKB:P01175}.
DISULFID 98 116 {ECO:0000250|UniProtKB:P01175}.
DISULFID 105 110 {ECO:0000250|UniProtKB:P01175}.
VARIANT 17 17 S -> F (in NDI).
{ECO:0000269|PubMed:8554046}.
/FTId=VAR_004980.
VARIANT 19 19 A -> T (in NDI; probably causes
insufficient processing of precursor;
dbSNP:rs387906511).
{ECO:0000269|PubMed:12519420,
ECO:0000269|PubMed:14673472,
ECO:0000269|PubMed:8370682,
ECO:0000269|PubMed:8514868,
ECO:0000269|PubMed:8554046,
ECO:0000269|PubMed:9580132}.
/FTId=VAR_004981.
VARIANT 19 19 A -> V (in NDI; dbSNP:rs387906512).
{ECO:0000269|PubMed:14673472,
ECO:0000269|PubMed:8554046}.
/FTId=VAR_004982.
VARIANT 21 21 Y -> H (in NDI; dbSNP:rs121964893).
{ECO:0000269|PubMed:12107248}.
/FTId=VAR_015262.
VARIANT 26 26 P -> L (in NDI; weakly active;
dbSNP:rs142886338).
{ECO:0000269|PubMed:10369876}.
/FTId=VAR_015263.
VARIANT 45 45 G -> R (in NDI).
{ECO:0000269|PubMed:8554046}.
/FTId=VAR_004983.
VARIANT 48 48 G -> V (in NDI; dbSNP:rs121964883).
{ECO:0000269|PubMed:1740104}.
/FTId=VAR_004984.
VARIANT 51 51 R -> C (in NDI).
{ECO:0000269|PubMed:8554046}.
/FTId=VAR_004985.
VARIANT 52 52 C -> R (in NDI).
/FTId=VAR_015264.
VARIANT 54 54 G -> R (in NDI; dbSNP:rs121964888).
{ECO:0000269|PubMed:10487710,
ECO:0000269|PubMed:11980620,
ECO:0000269|PubMed:14673472}.
/FTId=VAR_015265.
VARIANT 54 54 G -> V (in NDI; dbSNP:rs121964887).
{ECO:0000269|PubMed:9360520}.
/FTId=VAR_015266.
VARIANT 55 55 P -> L (in NDI).
{ECO:0000269|PubMed:8045958}.
/FTId=VAR_004986.
VARIANT 58 58 C -> F (in NDI).
{ECO:0000269|PubMed:12931042}.
/FTId=VAR_029997.
VARIANT 59 59 C -> R (in NDI).
/FTId=VAR_015267.
VARIANT 59 59 C -> Y (in NDI).
{ECO:0000269|PubMed:11150885}.
/FTId=VAR_015268.
VARIANT 67 67 V -> A (in NDI; dbSNP:rs28934878).
{ECO:0000269|PubMed:14673472}.
/FTId=VAR_019273.
VARIANT 78 78 E -> G (in NDI).
{ECO:0000269|PubMed:14673472,
ECO:0000269|PubMed:8554046}.
/FTId=VAR_004988.
VARIANT 78 78 Missing (in NDI).
{ECO:0000269|PubMed:14673472,
ECO:0000269|PubMed:8103767}.
/FTId=VAR_004987.
VARIANT 81 81 L -> P (in NDI).
{ECO:0000269|PubMed:8554046}.
/FTId=VAR_004989.
VARIANT 82 82 P -> L (in dbSNP:rs5195).
/FTId=VAR_011894.
VARIANT 87 87 S -> F (in NDI; dbSNP:rs121964890).
{ECO:0000269|PubMed:9814475}.
/FTId=VAR_015269.
VARIANT 88 88 G -> R (in NDI).
{ECO:0000269|PubMed:8554046}.
/FTId=VAR_004990.
VARIANT 88 88 G -> S (in NDI; dbSNP:rs121964882).
{ECO:0000269|PubMed:8554046}.
/FTId=VAR_004991.
VARIANT 92 92 C -> S (in NDI).
{ECO:0000269|PubMed:12012274,
ECO:0000269|PubMed:8554046}.
/FTId=VAR_004992.
VARIANT 92 92 C -> Y (in NDI; dbSNP:rs121964891).
{ECO:0000269|PubMed:11980620,
ECO:0000269|PubMed:9814475}.
/FTId=VAR_015270.
VARIANT 93 93 G -> W (in NDI; dbSNP:rs121964885).
{ECO:0000269|PubMed:7714110}.
/FTId=VAR_004993.
VARIANT 96 96 G -> C (in NDI).
{ECO:0000269|PubMed:14673472,
ECO:0000269|PubMed:8554046}.
/FTId=VAR_004994.
VARIANT 96 96 G -> D (in NDI).
{ECO:0000269|PubMed:14673472}.
/FTId=VAR_019274.
VARIANT 96 96 G -> V (in NDI; dbSNP:rs121964886).
/FTId=VAR_015271.
VARIANT 97 97 R -> C (in NDI).
/FTId=VAR_015272.
VARIANT 97 97 R -> P (in NDI).
{ECO:0000269|PubMed:11748489}.
/FTId=VAR_015273.
VARIANT 98 98 C -> G (in NDI).
{ECO:0000269|PubMed:11161827}.
/FTId=VAR_015274.
VARIANT 98 98 C -> S (in NDI).
{ECO:0000269|PubMed:15538939}.
/FTId=VAR_029998.
VARIANT 99 99 A -> P (in NDI).
{ECO:0000269|PubMed:14510916}.
/FTId=VAR_029999.
VARIANT 104 104 C -> F (in NDI).
{ECO:0000269|PubMed:12359138}.
/FTId=VAR_015275.
VARIANT 104 104 C -> G (in NDI).
{ECO:0000269|PubMed:14673472}.
/FTId=VAR_019275.
VARIANT 105 105 C -> R (in NDI).
{ECO:0000269|PubMed:11980620}.
/FTId=VAR_015276.
VARIANT 105 105 C -> Y (in NDI).
{ECO:0000269|PubMed:10677561}.
/FTId=VAR_015279.
VARIANT 116 116 C -> G (in NDI; strong accumulation in
the endoplasmic reticulum and an altered
morphology of this organelle;
dbSNP:rs74315383).
{ECO:0000269|PubMed:11017955,
ECO:0000269|PubMed:11443218}.
/FTId=VAR_015277.
VARIANT 116 116 C -> R (in NDI).
{ECO:0000269|PubMed:11017955}.
/FTId=VAR_015278.
VARIANT 116 116 C -> W (in NDI).
{ECO:0000269|PubMed:14673472}.
/FTId=VAR_019276.
VARIANT 119 119 G -> V (in dbSNP:rs1051744).
{ECO:0000269|Ref.5}.
/FTId=VAR_011895.
MUTAGEN 28 28 G->V: Gain of antagonist activity on
V1aR/AVPR1A (and loss of agonist activity
on this receptor). 42-fold decrease in
affinity for V1aR/AVPR1A, 2000-fold
decrease in affinity for V1bR/AVPR1B, 5-
fold decrease in affinity for V2R/AVPR2
and no change in affinity for oxytocin
receptor (OXTR).
{ECO:0000269|PubMed:18174156}.
CONFLICT 11 11 L -> P (in Ref. 1; AAA98772).
{ECO:0000305}.
CONFLICT 48 48 G -> D (in Ref. 5; AAB86629).
{ECO:0000305}.
SEQUENCE 164 AA; 17325 MW; 8F5EF9834700B9AE CRC64;
MPDTMLPACF LGLLAFSSAC YFQNCPRGGK RAMSDLELRQ CLPCGPGGKG RCFGPSICCA
DELGCFVGTA EALRCQEENY LPSPCQSGQK ACGSGGRCAA FGVCCNDESC VTEPECREGF
HRRARASDRS NATQLDGPAG ALLLRLVQLA GAPEPFEPAQ PDAY


Related products :

Catalog number Product name Quantity
E0365p ELISA kit AVP,AVP-NPII,Pig,Sus scrofa,Vasopressin-neurophysin 2-copeptin 96T
U0365p CLIA AVP,AVP-NPII,Pig,Sus scrofa,Vasopressin-neurophysin 2-copeptin 96T
E0365p ELISA AVP,AVP-NPII,Pig,Sus scrofa,Vasopressin-neurophysin 2-copeptin 96T
E0365r ELISA Avp,AVP-NPII,Rat,Rattus norvegicus,Vasopressin-neurophysin 2-copeptin 96T
U0365m CLIA Avp,AVP-NPII,Mouse,Mus musculus,Vasopressin-neurophysin 2-copeptin 96T
U0365r CLIA Avp,AVP-NPII,Rat,Rattus norvegicus,Vasopressin-neurophysin 2-copeptin 96T
E0365r ELISA kit Avp,AVP-NPII,Rat,Rattus norvegicus,Vasopressin-neurophysin 2-copeptin 96T
U0365b CLIA AVP,AVP-NPII,Bos taurus,Bovine,Vasopressin-neurophysin 2-copeptin 96T
E0365b ELISA AVP,AVP-NPII,Bos taurus,Bovine,Vasopressin-neurophysin 2-copeptin 96T
E0365b ELISA kit AVP,AVP-NPII,Bos taurus,Bovine,Vasopressin-neurophysin 2-copeptin 96T
E0365m ELISA kit Avp,AVP-NPII,Mouse,Mus musculus,Vasopressin-neurophysin 2-copeptin 96T
E0365m ELISA Avp,AVP-NPII,Mouse,Mus musculus,Vasopressin-neurophysin 2-copeptin 96T
E0365h ELISA kit ARVP,AVP,AVP-NPII,Homo sapiens,Human,Vasopressin-neurophysin 2-copeptin,VP 96T
E0365h ELISA ARVP,AVP,AVP-NPII,Homo sapiens,Human,Vasopressin-neurophysin 2-copeptin,VP 96T
U0365h CLIA ARVP,AVP,AVP-NPII,Homo sapiens,Human,Vasopressin-neurophysin 2-copeptin,VP 96T
ER285 Vasopressin-neurophysin 2-copeptin Elisa Kit 96T
I2077 Vasopressin-neurophysin 2-copeptin (AVP), Pig, ELISA Kit 96T
EH872 Vasopressin-neurophysin 2-copeptin Elisa Kit 96T
I2078 Vasopressin-neurophysin 2-copeptin (AVP), Sheep, ELISA Kit 96T
CSB-EL002466HO Horse Vasopressin-neurophysin 2-copeptin(AVP) ELISA kit 96T
I2075 Vasopressin-neurophysin 2-copeptin (AVP), Bovine, ELISA Kit 96T
I2076 Vasopressin-neurophysin 2-copeptin (AVP), Horse, ELISA Kit 96T
CSB-RP110644h Recombinant human Vasopressin-neurophysin 2-copeptin 500ug
CSB-EL002466BO Bovine Vasopressin-neurophysin 2-copeptin(AVP) ELISA kit 96T
AE54801SH Sheep Vasopressin-neurophysin 2-copeptin (AVP) ELISA Kit 48T

Kits Elisa; taq POLYMERASE

Search in Google:

google

Share this page:
share on twitter rss feedsfacebookgoogle gentaur



Quick order!
Enter catalog number :


Gentaur; yes we can

Pathways :
WP1621: Arginine and proline metabolism
WP1642: D-Arginine and D-ornithine metabolism
WP2155: arginine biosynthesis
WP275: Arginine Biosynthesis
WP54: Arginine degradation

Related Genes :
[AVP] Vasopressin-neurophysin 2-copeptin (AVP-NPII) [Cleaved into: Lys-vasopressin; Neurophysin 2 (Neurophysin-I/-III); Copeptin]
[OXT OT] Oxytocin-neurophysin 1 (OT-NPI) [Cleaved into: Oxytocin (Ocytocin); Neurophysin 1]
[Avpr1a] Vasopressin V1a receptor (V1aR) (AVPR V1a) (Antidiuretic hormone receptor 1a) (Vascular/hepatic-type arginine vasopressin receptor)
[Nlrp6 Nalp6 Navr Pypaf5] NACHT, LRR and PYD domains-containing protein 6 (Angiotensin II/vasopressin receptor) (Non-angiotensin-vasopressin receptor) (Non-AVR) (PYRIN-containing APAF1-like protein 5-like)
[AVP] Neurophysin 2 (E-NP) (Neurophysin-II)
[Cul5 Vacm1] Cullin-5 (CUL-5) (Vasopressin-activated calcium-mobilizing receptor 1) (VACM-1)
[AQP2] Aquaporin-2 (AQP-2) (ADH water channel) (Aquaporin-CD) (AQP-CD) (Collecting duct water channel protein) (WCH-CD) (Water channel protein for renal collecting duct)
[CUL5 VACM1] Cullin-5 (CUL-5) (Vasopressin-activated calcium-mobilizing receptor 1) (VACM-1)
[NLRP3 C1orf7 CIAS1 NALP3 PYPAF1] NACHT, LRR and PYD domains-containing protein 3 (Angiotensin/vasopressin receptor AII/AVP-like) (Caterpiller protein 1.1) (CLR1.1) (Cold-induced autoinflammatory syndrome 1 protein) (Cryopyrin) (PYRIN-containing APAF1-like protein 1)
[F2RL1 GPR11 PAR2] Proteinase-activated receptor 2 (PAR-2) (Coagulation factor II receptor-like 1) (G-protein coupled receptor 11) (Thrombin receptor-like 1) [Cleaved into: Proteinase-activated receptor 2, alternate cleaved 1; Proteinase-activated receptor 2, alternate cleaved 2]
[gag-pol] Gag-Pol polyprotein [Cleaved into: Matrix protein p19; p2A; p2B; p10; Capsid protein p27, alternate cleaved 1; Capsid protein p27, alternate cleaved 2; Spacer peptide (SP) (p3); Nucleocapsid protein p12; Protease p15 (EC 3.4.23.-); Reverse transcriptase, beta-subunit (RT-beta); Reverse transcriptase, alpha-subunit (RT-alpha) (EC 2.7.7.49) (EC 2.7.7.7) (EC 3.1.26.4); Integrase (IN) (EC 2.7.7.-) (EC 3.1.-.-) (pp32); p4]
[gag] Gag polyprotein [Cleaved into: Matrix protein p19; p2A; p2B; p10; Capsid protein p27, alternate cleaved 1; Capsid protein p27, alternate cleaved 2; Spacer peptide (SP) (p3); Nucleocapsid protein p12; Protease p15 (EC 3.4.23.-)]
[gag-pol] Gag-Pol polyprotein [Cleaved into: Matrix protein p19; p2A; p2B; p10; Capsid protein p27, alternate cleaved 1; Capsid protein p27, alternate cleaved 2; p3; Nucleocapsid protein p12; Protease p15 (EC 3.4.23.-); Reverse transcriptase beta-subunit (RT-beta); Reverse transcriptase alpha-subunit (RT-alpha) (EC 2.7.7.49) (EC 2.7.7.7) (EC 3.1.26.4); Integrase (IN) (EC 2.7.7.-) (EC 3.1.-.-) (pp32); p4]
[gag-pol] Gag-Pol polyprotein [Cleaved into: Matrix protein p19; p2A; p2B; p10; p3; Capsid protein p27, alternate cleaved 1; Capsid protein p27, alternate cleaved 2; Nucleocapsid protein p12; Protease p15 (EC 3.4.23.-); Reverse transcriptase beta-subunit (RT-beta); Reverse transcriptase alpha-subunit (RT-alpha) (EC 2.7.7.49) (EC 2.7.7.7) (EC 3.1.26.4); Integrase (IN) (EC 2.7.7.-) (EC 3.1.-.-) (pp32); p4]
[arg-6 orn-2 NCU00567] Protein arg-6, mitochondrial [Cleaved into: N-acetyl-gamma-glutamyl-phosphate reductase (EC 1.2.1.38) (N-acetyl-glutamate semialdehyde dehydrogenase) (NAGSA dehydrogenase); Acetylglutamate kinase (EC 2.7.2.8) (N-acetyl-L-glutamate 5-phosphotransferase) (NAG kinase) (AGK)]
[SRRM2 KIAA0324 SRL300 SRM300 HSPC075] Serine/arginine repetitive matrix protein 2 (300 kDa nuclear matrix antigen) (Serine/arginine-rich splicing factor-related nuclear matrix protein of 300 kDa) (SR-related nuclear matrix protein of 300 kDa) (Ser/Arg-related nuclear matrix protein of 300 kDa) (Splicing coactivator subunit SRm300) (Tax-responsive enhancer element-binding protein 803) (TaxREB803)
[Slc14a2 Ut2] Urea transporter 2 (Solute carrier family 14 member 2) (Urea transporter, kidney)
[] Genome polyprotein [Cleaved into: Capsid protein C (Core protein); Protein prM; Peptide pr; Small envelope protein M (Matrix protein); Envelope protein E; Non-structural protein 1 (NS1); Non-structural protein 2A (NS2A); Serine protease subunit NS2B (Flavivirin protease NS2B regulatory subunit) (Non-structural protein 2B); Serine protease NS3 (EC 3.4.21.91) (EC 3.6.1.15) (EC 3.6.4.13) (Flavivirin protease NS3 catalytic subunit) (Non-structural protein 3); Non-structural protein 4A (NS4A); Peptide 2k; Non-structural protein 4B (NS4B); RNA-directed RNA polymerase NS5 (EC 2.1.1.56) (EC 2.1.1.57) (EC 2.7.7.48) (Non-structural protein 5)]
[Pla2g6 Pnpla9] 85/88 kDa calcium-independent phospholipase A2 (CaI-PLA2) (EC 3.1.1.4) (Group VI phospholipase A2) (GVI PLA2) (Intracellular membrane-associated calcium-independent phospholipase A2 beta) (iPLA2-beta) (Patatin-like phospholipase domain-containing protein 9) (PNPLA9)
[PRMT5 HRMT1L5 IBP72 JBP1 SKB1] Protein arginine N-methyltransferase 5 (EC 2.1.1.320) (72 kDa ICln-binding protein) (Histone-arginine N-methyltransferase PRMT5) (Jak-binding protein 1) (Shk1 kinase-binding protein 1 homolog) (SKB1 homolog) (SKB1Hs) [Cleaved into: Protein arginine N-methyltransferase 5, N-terminally processed]
[] Genome polyprotein [Cleaved into: Capsid protein C (Capsid protein) (Core protein); Protein prM (Precursor membrane protein); Peptide pr (Peptide precursor); Small envelope protein M (Matrix protein); Envelope protein E; Non-structural protein 1 (NS1); Non-structural protein 2A (NS2A); Serine protease subunit NS2B (Flavivirin protease NS2B regulatory subunit) (Non-structural protein 2B); Serine protease NS3 (EC 3.4.21.91) (EC 3.6.1.15) (EC 3.6.4.13) (Flavivirin protease NS3 catalytic subunit) (Non-structural protein 3); Non-structural protein 4A (NS4A); Peptide 2k; Non-structural protein 4B (NS4B); RNA-directed RNA polymerase NS5 (EC 2.1.1.56) (EC 2.1.1.57) (EC 2.7.7.48) (Non-structural protein 5)]
[] Genome polyprotein [Cleaved into: Capsid protein C (Core protein); Protein prM; Peptide pr; Small envelope protein M (Matrix protein); Envelope protein E; Non-structural protein 1 (NS1); Non-structural protein 2A (NS2A); Serine protease subunit NS2B (Flavivirin protease NS2B regulatory subunit) (Non-structural protein 2B); Serine protease NS3 (EC 3.4.21.91) (EC 3.6.1.15) (EC 3.6.4.13) (Flavivirin protease NS3 catalytic subunit) (Non-structural protein 3); Non-structural protein 4A (NS4A); Peptide 2k; Non-structural protein 4B (NS4B); RNA-directed RNA polymerase NS5 (EC 2.1.1.56) (EC 2.1.1.57) (EC 2.7.7.48) (Non-structural protein 5)]
[] Genome polyprotein [Cleaved into: Capsid protein C (Core protein); Protein prM; Peptide pr; Small envelope protein M (Matrix protein); Envelope protein E; Non-structural protein 1 (NS1); Non-structural protein 2A (NS2A); Serine protease subunit NS2B (Flavivirin protease NS2B regulatory subunit) (Non-structural protein 2B); Serine protease NS3 (EC 3.4.21.91) (EC 3.6.1.15) (EC 3.6.4.13) (Flavivirin protease NS3 catalytic subunit) (Non-structural protein 3); Non-structural protein 4A (NS4A); Peptide 2k; Non-structural protein 4B (NS4B); RNA-directed RNA polymerase NS5 (EC 2.1.1.56) (EC 2.1.1.57) (EC 2.7.7.48) (Non-structural protein 5)]
[] Genome polyprotein [Cleaved into: Capsid protein C (Core protein); Protein prM; Peptide pr; Small envelope protein M (Matrix protein); Envelope protein E; Non-structural protein 1 (NS1); Non-structural protein 2A (NS2A); Serine protease subunit NS2B (Flavivirin protease NS2B regulatory subunit) (Non-structural protein 2B); Serine protease NS3 (EC 3.4.21.91) (EC 3.6.1.15) (EC 3.6.4.13) (Flavivirin protease NS3 catalytic subunit) (Non-structural protein 3); Non-structural protein 4A (NS4A); Peptide 2k; Non-structural protein 4B (NS4B); RNA-directed RNA polymerase NS5 (EC 2.1.1.56) (EC 2.1.1.57) (EC 2.7.7.48) (Non-structural protein 5)]
[Nos2] Nitric oxide synthase, inducible (EC 1.14.13.39) (Inducible NO synthase) (Inducible NOS) (iNOS) (NOS type II) (Peptidyl-cysteine S-nitrosylase NOS2)
[prmt-5 tag-251 C34E10.5] Protein arginine N-methyltransferase 5 (EC 2.1.1.320)
[botA atx bna bonT CLM_0897] Botulinum neurotoxin type A2 (BoNT/A) (Bontoxilysin-A) (BOTOX) [Cleaved into: Botulinum neurotoxin A2 light chain (LC) (EC 3.4.24.69); Botulinum neurotoxin A2 heavy chain (HC)]
[Ppp2r2b] Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B beta isoform (PP2A subunit B isoform B55-beta) (PP2A subunit B isoform BRB) (PP2A subunit B isoform PR55-beta) (PP2A subunit B isoform R2-beta) (PP2A subunit B isoform beta)
[] Genome polyprotein [Cleaved into: Capsid protein C (Core protein); Protein prM; Peptide pr; Small envelope protein M (Matrix protein); Envelope protein E; Non-structural protein 1 (NS1); Non-structural protein 2A (NS2A); Serine protease subunit NS2B (Flavivirin protease NS2B regulatory subunit) (Non-structural protein 2B); Serine protease NS3 (EC 3.4.21.91) (EC 3.6.1.15) (EC 3.6.4.13) (Flavivirin protease NS3 catalytic subunit) (Non-structural protein 3); Non-structural protein 4A (NS4A); Peptide 2k; Non-structural protein 4B (NS4B); RNA-directed RNA polymerase NS5 (EC 2.1.1.56) (EC 2.1.1.57) (EC 2.7.7.48) (Non-structural protein 5)]
[] Genome polyprotein [Cleaved into: Capsid protein C (Core protein); Protein prM; Peptide pr; Small envelope protein M (Matrix protein); Envelope protein E; Non-structural protein 1 (NS1); Non-structural protein 2A (NS2A); Serine protease subunit NS2B (Flavivirin protease NS2B regulatory subunit) (Non-structural protein 2B); Serine protease NS3 (EC 3.4.21.91) (EC 3.6.1.15) (EC 3.6.4.13) (Flavivirin protease NS3 catalytic subunit) (Non-structural protein 3); Non-structural protein 4A (NS4A); Peptide 2k; Non-structural protein 4B (NS4B); RNA-directed RNA polymerase NS5 (EC 2.1.1.56) (EC 2.1.1.57) (EC 2.7.7.48) (Non-structural protein 5)]

Bibliography :